Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:11 pm Purchase | 2024-09-30 | 13G | 908 Devices Inc. MASS | ARCH Venture Fund VII L.P. | 5,782,548 16.600% | 26,106 (+0.45%) | Filing History |
| 2024-02-09 5:34 pm Purchase | 2023-12-31 | 13G | 908 Devices Inc. MASS | ARCH Venture Fund VII L.P. | 5,756,442 17.800% | 11,843 (+0.21%) | Filing History |
| 2023-02-13 4:06 pm Purchase | 2022-12-31 | 13G | 908 Devices Inc. MASS | ARCH Venture Fund VII L.P. | 5,744,599 18.100% | 12,313 (+0.21%) | Filing History |
| 2022-02-11 4:55 pm Purchase | 2021-12-31 | 13G | Unity Biotechnology, Inc. UBX | ARCH Venture Fund VII L.P. | 1,013,886 17.500% | 3,856 (+0.38%) | Filing History |
| 2022-02-08 3:03 pm Purchase | 2021-12-31 | 13G | 908 Devices Inc. MASS | ARCH Venture Fund VII L.P. | 5,732,286 18.500% | 6,440 (+0.11%) | Filing History |
| 2021-02-04 2:03 pm Purchase | 2020-12-31 | 13G | 908 Devices Inc. MASS | ARCH Venture Fund VII L.P. | 5,725,846 21.100% | 5,725,846 (New Position) | Filing History |
| 2021-02-02 5:03 pm Purchase | 2020-12-31 | 13G | Unity Biotechnology, Inc. UBX | ARCH Venture Fund VII L.P. | 1,010,030 19.100% | 3,856 (+0.38%) | Filing History |
| 2021-02-02 5:02 pm Sale | 2020-12-31 | 13G | Twist Bioscience Corporation TWST | ARCH Venture Fund VII L.P. | 0 0.000% | -3,367,158 (Position Closed) | Filing History |
| 2021-02-02 5:02 pm Sale | 2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | ARCH Venture Fund VII L.P. | 0 0.000% | -334,177 (Position Closed) | Filing History |